Navigation Links
23ème congrès européen sur l'Hypertension et la Protection Cardiovasculaire
Date:6/25/2013

#233;sartan /amlodipine 40/10 mg qui a réduit la pression artérielle centrale de manière significativement plus importante. Plus la baisse de la pression artérielle est importante, plus le risque d'événements cardiovasculaires pourrait être faible," a commenté le Professeur Luis Ruilope, investigateur principal de l'étude SEVITENSION.

NOTES AUX RÉDACTEURS

A propos de Sevikar®

Sevikar® est une association fixe d'olmésartan et amlodipine :[10]

  • L'olmésartan est un antagoniste des récepteurs de l'angiotensine II (ARA II) qui agit en empêchant l'action de l'angiotensine II. L'angiotensine II provoque une vasoconstriction et entraîne la production d'aldostérone, une autre hormone qui stimule la rétention d'eau dans l'organisme. En bloquant l'action de l'angiotensine II, l'olmésartan dilate les vaisseaux sanguins et réduit le volume de liquide circulant dans le sang, faisant ainsi baisser la pression artérielle. L'amlodipine est un inhibiteur calcique à longue durée d'action indiqué pour réduire la pression artérielle. L'amlodipine agit en relâchant les muscles lisses de la paroi des artères, provoquant ainsi une diminution de la résistance périphérique totale et par conséquent une baisse de la pression artérielle.

En plus d'une action puissante sur la baisse de la pression artérielle, l'association Olmesartan et Amlodipine offre un mode d'administration pratique avec une seule prise par jour d'un comprimé, permettant à la majorité des patients d'atteindre leur objectif de pression artérielle.

A propos des associations thérapeutiques (d'après les recommandations européennes sur la prise en charge de l'hypertensio
'/>"/>

SOURCE Daiichi Sankyo Europe GmbH
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Members of Congress, Cancer Experts Address Impact of Genetic Testing on Cancer
2. Experts Launch the Alliance for Fertility Preservation at the International Society for Fertility Preservations 2nd World Congress
3. Global Leaders in Advanced Biofuels Industry Urge Congressional Leaders to Extend Critical Tax Provisions
4. Nation Must Invest in Biomedical Research/Health Workforce, AAHC President Tells Congress
5. PharmAthene Presents Update on SparVax™ rPA Anthrax Vaccine Program at the 2012 World Vaccine Congress
6. Neuralstem CEO to Present at the World Stem Cells and Regenerative Medicine Congress in London
7. ETEX Corporation to present at the 9th World Biomaterial Congress
8. Discovery Labs to Present AFECTAIR® Data at European Congress on Pediatric and Neonatal Ventilation
9. PROLOR Biotech Announces Presentation of Data on Its Long-Acting Clotting Factors at World Federation of Hemophilia World Congress
10. The Legends that Contributed to Silicon Valleys Eminence Assemble for Frost & Sullivans Growth, Innovation and Leadership 2012 Congress
11. BIOCOM Announces Endorsement in 52nd Congressional District Race
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... , June 29, 2015 ... has announced the addition of the "Biotechnology ... Biotechnology for the Non-Biotechnologist, ideal for ... theory, principles, techniques and potential of biotechnology. ... understand the basic theory, principles, techniques, and potential ...
(Date:7/6/2015)... ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) ... Novella Clinical (Novella), to conduct the phase 3 ... glioblastoma. Novella is a full-service, global clinical research organization ... oncology companies. The ICT-107 phase 3 trial will include ... Europe and Canada , ...
(Date:7/3/2015)... , July 3, 2015 /PRNewswire/ ... hakea verkossa osoitteessa  http://www.openinnovationinscience.at ... Innovation in Science" -jatkokoulutusohjelmaan 22.7.2015 ... Gesellschaftin (LBG) tekemän, kansainvälisiä tutkijoita ... terveystieteiden kaksi suurinta haastetta ovat ...
(Date:7/3/2015)... , July 3, 2015 ... till 22 september 2015 på  http://www.openinnovationinscience.at ... Innovation in Science" som hålls i ... en färsk undersökning med internationella forskare och ... (LBG) är hälsovetenskapens två största utmaningar bristen ...
Breaking Biology Technology:ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 3Lansering av världens första program för öppen innovation för att utbilda forskare 2Lansering av världens första program för öppen innovation för att utbilda forskare 3
... Reportlinker.com announces that a new market research report ... Biomarkers - Technologies,markets and companies ... follows the broad definition of a biomarker as ... evaluated as an indicator of normal biological or ...
... 2011 Reportlinker.com announces that a new ... catalogue: The 2011 Blood ... Opportunities and Business Expansion Strategies for Suppliers ... During the next ten years, the ...
... YORK, March 7, 2011 NeoStem, Inc. (NYSE Amex: ... operations in the U.S. and China, is pleased to ... Vice President of Strategic Business Development. Jason was formerly ... the firm,s research effort in emerging biotechnology companies. Jason,s ...
Cached Biology Technology:Reportlinker Adds Biomarkers - Technologies, Markets and Companies 2Reportlinker Adds The 2011 Blood Banking Market: US, Europe, Japan - Emerging Opportunities and Business Expansion Strategies for Suppliers 2NeoStem Announces the Addition of Jason Kolbert as Vice President of Strategic Business Development 2NeoStem Announces the Addition of Jason Kolbert as Vice President of Strategic Business Development 3
(Date:7/2/2015)... 2, 2015 Fingerprint Cards has received ... and FPC1155 from the distributor World Peace Industrial Group (WPI), ... in Asia . Deliveries are planned to ... be used by smartphone manufacturers in Asia ... the communicated revenue guidance of approximately 2,200 MSEK for 2015. ...
(Date:6/26/2015)... ATL Technology, LLC, a top provider of electromechanical contract manufacturing ... headquartered in Springville, Utah , has announced ... corporation with locations in Santa Clara, CA ... ). This acquisition will incorporate MedConx,s manufacturing facility ... existing facility in Costa Rica , resulting ...
(Date:6/24/2015)... , June 24, 2015 The biologics safety ... major drivers for the market include growth of the ... new drug launches. Over the years, the number of ... 2001 and 2010, the FDA approved 225 drug applications ... WIPO, Europe accounted for 3,822 ...
Breaking Biology News(10 mins):FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4
... Netherlands,Thursday 25 April 2013: Probiotics could emerge as ... therapy after a new study announced at ... reduced development of the notoriously difficult-to-treat disease. ... preventing the development of HE in 160 cirrhotic ...
... Liver Congress 2013 include results from early in vitro ... (cccDNA), which may form the basis of a cure ... cccDNA is organized into mini-chromosomes within the nucleus of ... availability of efficient therapies against HBV, long-term persistence of ...
... 2013, a novel H7N9 influenza virus was identified in ... in humans, resulting in some deaths. A group of ... Reference Laboratory, State Key Laboratory of Veterinary Biotechnology, Harbin ... investigated the origins of this novel H7N9 influenza virus ...
Cached Biology News:Probiotics found to reduce hepatic encephalopathy 2Novel therapeutic approaches to cure chronic HBV infection 2Novel therapeutic approaches to cure chronic HBV infection 3Source identification of H7N9 influenza virus causing human infections 2Source identification of H7N9 influenza virus causing human infections 3
Duck polyclonal to Cobra venom - Fab Fragment ( Abpromise for all tested applications). Antigen: Snake Venom of N. naja arta...
Anti-human C5a/C5a des-Arg (neo-epitode), Clone 2952, Monoclonal Antibody...
...
Reacts with the 80 kDa fragment of the M-chain of human merosin....
Biology Products: